We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Evotec and Boehringer Ingelheim Enter into Target Discovery Collaboration in Alzheimer’s Disease

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Evotec AG has announced a multi-year collaboration with Boehringer Ingelheim to jointly identify targets as potential points of intervention in the treatment of Alzheimer’s disease (AD). The collaboration will also involve the Research Institute of Molecular Pathology in Vienna (IMP).
Evotec scientists together with the IMP will apply their and well validated disease models to identify AD targets. Based on these models, Boehringer Ingelheim will select and further validate target candidates for its in-house drug discovery programme with the goal of developing innovative therapeutics. Financial details of this collaboration are not disclosed.

The contract also includes an option for Evotec to support Boehringer Ingelheim (BI) in the target validation process. If BI exercises this option, Evotec is eligible for milestone payments of up to EUR 20 million plus royalties.

“Over the past years, Evotec has built significant expertise in the field of Alzheimer’s and other neurodegenerative diseases, and our innovative discovery tools and approaches have successfully been proven together with renowned industry partners. We are delighted that this collaboration expands our ongoing successful partnership with Boehringer Ingelheim into another area of our strength,” said Joern Aldag, President and Chief Executive Officer of Evotec.